Palvella Therapeutics (NASDAQ:PVLA) Shares Down 7.9% – Should You Sell?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares dropped 7.9% on Wednesday . The company traded as low as $140.95 and last traded at $140.71. 103,392 shares were traded during mid-day trading, a decline of 64% from the average daily volume of 286,451 shares. The stock had previously closed at $152.82.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Stephens reissued an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. HC Wainwright raised their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday. Finally, Chardan Capital reiterated a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Palvella Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Down 10.4%

The firm’s fifty day moving average price is $119.85 and its 200-day moving average price is $111.05. The stock has a market cap of $1.96 billion, a P/E ratio of -32.78 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Sell-side analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. First Light Asset Management LLC bought a new stake in Palvella Therapeutics in the 3rd quarter worth approximately $33,949,000. Summit Partners Public Asset Management LLC lifted its holdings in shares of Palvella Therapeutics by 1,016.0% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after buying an additional 354,525 shares during the period. Vanguard Group Inc. boosted its stake in shares of Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after buying an additional 330,847 shares during the last quarter. State Street Corp boosted its position in Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Palvella Therapeutics by 262.4% during the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after buying an additional 280,573 shares during the period. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.